35
Participants
Start Date
July 5, 2023
Primary Completion Date
March 15, 2024
Study Completion Date
March 15, 2024
SYNB1934v1
SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
Placebo
Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Medical University of South Carolina, Pediatrics, Charleston
University of Florida - Gainesville, Gainesville
Dokuz Eylül Üniversitesi Araştırma ve Uygulama Hastanesi, Balçova
Division of Medical Genetics-Pediatrics, Vanderbilt University Medical Center, Nashville
UT Southwestern Medical Center, Dallas
McGovern Medical School/Memorial Hermann Hospital, Houston
University of Colorado Children's Hospital, Aurora
Science 37, Culver City
Children's Hospital Orange County, Orange
Stanford University, Department of Pediatrics, Palo Alto
Oregon Health and Science University Department of Molecular and Medical Genetics, Portland
Ann & Robert H. Lurie Children's Hospital of Chicago, Pediatrics, Chicago
Massachusetts General Hospital, Department of Pediatrics, Boston
MAGIC Clinic, Calgary
Hamilton Health Sciences Corporation, Hamilton
Children's Hospital of Eastern Ontario, Ottawa
University Health Network, Toronto
Medical Genetics and Laboratory Diagnostics Center, Tbilisi
Gazi Üniversitesi Hastanesi, Yenimahalle
Lead Sponsor
Synlogic
INDUSTRY